Previous projects

Please select a project below to view more detail.

    2011

  1. Research and development of medical products: opportunities and challenges
  2. Statement on water and health
  3. Statement on mental health policy issues
  4. Academy response to Royal Society consultation on 'Science as a public enterprise'
  5. Diabetes & obesity: getting to the heart of the matter

    6. 2010

  6. Inter Academy Medical Panel Statement on the health co-benefits of policies to tackle climate change
  7. Statement on the health of women and children
  8. Academy submissions to the spending review consultation 2010
  9. Biomedical research - a platform for increasing health and wealth in the UK
  10. Redressing the balance: the status and valuation of teaching in academic careers
  11. Reaping the rewards: a vision for UK medical science
  12. Revalidation reforms

    13. 2009

  13. Academia, industry and the NHS: collaboration and innovation
  14. Rejuvenating ageing research
  15. Genome-wide association studies: understanding the genetics of common disease
  16. Global health diagnostics: research, development and regulation
  17. Biotechnology innovation: opportunities and challenges
  18. Research in general practice

    19. 2008

  19. Global mental health
  20. Brain science, addiction and drugs
  21. Inter-species embryos
  22. Building clinical academic capacity and the allocation of resources across academic specialties

    23. 2007

  23. Optimising stratified medicines R&D: addressing scientific and economic issues
  24. Identifying the environmental causes of disease
  25. Careers for biomedical scientists and clinicians in industry
  26. Modernising medical careers inquiry
  27. Systems biology

    28. 2006

  28. Personal data for public good: using health information in medical research
  29. Use of non-human primates in research
  30. Pandemic influenza
  31. Science of violence
  32. Reform of research funding and assessment
  33. Public health - ethical issues
  34. Sir David Cooksey's review of UK health research
  35. Medical research: assessing the benefits to society
  36. Research ethics committees
  37. MB PhD working group
  38. Testing antibody therapies

    39. 2005

  39. Safer Medicines
  40. Human tissue consultations
  41. RAE 2008 Consultation: Panel criteria and methods
  42. The freedom to succeed
  43. Mental Capacity Bill
  44. Strengthening health services research
  45. SARS
  46. Microbial challenge studies

    47. 2004

  47. Detection and identification of infectious disease
  48. The science of ageing
  49. Choosing health
  50. Restoring neurological function
  51. Calling time: the nation's drinking as a major health issue
  52. Science spending
  53. Research Assessment Exercise (RAE)
  54. Human tissue legislation

    55. 2003

  55. Strengthening clinical research

    56. 2002

  56. Unclaimed and unidentified organs
  57. Infectious disease in livestock
  58. The structure, constitution and governance of the General Medical Council

    59. 2001

  59. Transmissible spongiform encephalopathies (TSE)
  60. Vaccines - current status and future needs
*
*

Testing antibody therapies

Summary| Working Group Membership| Terms of Reference| Project Downloads

Summary:

In March 2006, six volunteers taking part in a phase I clinical trial of a monoclonal antibody, TGN1412, experienced severe adverse events. As part of the Academy of Medical Sciences’ on-going work into the research and development of new medicines, a small working group was convened to discuss some of the broad questions and issues arising from the TGN1412 trial.

back to top

Working Group Membership:

Professor Patrick Vallance FMedSci (Chair)
Head, Division of Medicine, University College London

Professor Richard Begent FMedSci
Professor of Clinical Oncology, Royal Free & University College Medical School

Professor Ray Hill FMedSci
Executive Director, Licensing and External Research, Neuroscience Research
Centre, Merck Sharp and Dohme

Dr David Jayne
Division of Renal Medicine, University of Cambridge

Sir Ravinder Maini FMedSci
Emeritus Professor of Rheumatology, Imperial College School of Medicine

Dr Anne O’Garra FMedSci
Head of Immunoregulation, National Institute for Medical Research

Professor Herman Waldmann FRS FMedSci
Head of Department, Sir William Dunn School of Pathology, University of Oxford

back to top

Terms of Reference:
The working group’s remit was to:
• Consider the potential role of antibody therapies as treatments;
• Identify potential safety hazards unique to the assessment of antibody therapies
• Provide a framework for further steps to ensure the safe introduction of new antibody therapies.

back to top

Project Downloads:

back to top

*
*
    Back to:
  1. Policy